BioSpace News Archive

GNS Healthcare (GNS), an artificial intelligence company creating in silico patients that simulate drug treatment at the individual patient level, today announced a multi-year collaboration with Memorial Sloan Kettering Cancer Center (MSK) to leverage longitudinal multi-modal prostate cancer patient data and world class prostate cancer expertise with GNS’ Gemini in silico Prostate Cancer patient.

Lexaria Bioscience Corp., a global innovator in drug delivery platforms is pleased to announce that its recent oral nicotine absorption study NIC-A21-1 revealed that DehydraTECHTM-nicotine delivered via the oral pouch product format required only 2 to 4 minutes to deliver nicotine levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls.

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the European Medicines Agency (EMA) has authorized a third dose of the Moderna COVID-19 vaccine (Spikevax) given at least 28 days after the second dose to severely immunocompromised individuals 12 years of age or older.

Adial Pharmaceuticals, Inc. today announced that the Company has been invited to present at the Fall Harvest - Best Ideas from the Buy-Side conference, which is being held virtually this week, October 5 - 8, 2021.

iotaMotion Inc., a leader in developing advanced surgical systems for cochlear implant surgery, announced FDA granted its’ De Novo classification request to market the iotaSOFT™ insertion system.

MicroPort Orthopedics, a global leader in orthopedic devices and technologies, announces that C. Lowry Barnes, MD, Chair of Orthopaedics at the University of Arkansas for Medical Sciences Health, has officially joined the company’s leadership team as Medical Director.

On October 21th at 9AM PST / 12PM EST , Dr. Kelly Wosnik , Owner/ NP-C of Bristol Health will share practice patterns and associated clinical implications using pharmacogenomic testing (PGx) to pinpoint the right treatments for mental illnesses.

Transaction concludes with the launch of “Awakn Clinics Oslo AS” as part of Awakn Life Sciences Nordic Expansion.

Data Shows Statistically Significant Improvements in Speed and Motor Function in PD Patients.

William A. Hartman, Halberd’s Chairman, President & CEO, stated, “We are pleased that our product will now also be available through Amazon, and will be able to reach virtually anyone in need of immunity support to maintain their body’s health and resistance to diseases.